Lecanemab-Associated Amyloid-β Protofibril in Cerebrospinal Fluid Correlates with Biomarkers of Neurodegeneration in Alzheimer’s Disease

Researchers aimed to characterize amyloid-β (Aβ) protofibril (PF) captured by lecanemab in human cerebrospinal fluid from living participants with different stages in Alzheimer’s Disease, which enabled an enhanced understanding of the dynamic changes of lecanemab-associated Aβ-PF in vivo.